Candel Therapeutics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Candel Therapeutics.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 20.7% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 02 Mar 2024 |
Recent future growth updates
Recent updates
Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
Apr 15Candel gets European orphan drug designation for brain, spinal cord tumor treatment
Sep 15Candel Therapeutics appoints CFO, chief medical officer
Sep 07Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies
Oct 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | N/A | -42 | N/A | N/A | 1 |
| 12/31/2023 | N/A | -38 | -35 | -34 | N/A |
| 9/30/2023 | 0 | -32 | -34 | -34 | N/A |
| 6/30/2023 | 0 | -32 | -35 | -34 | N/A |
| 3/31/2023 | 0 | -27 | -35 | -34 | N/A |
| 12/31/2022 | 0 | -19 | -33 | -31 | N/A |
| 9/30/2022 | 0 | -12 | -31 | -30 | N/A |
| 6/30/2022 | 0 | -20 | -29 | -27 | N/A |
| 3/31/2022 | 0 | -33 | -26 | -25 | N/A |
| 12/31/2021 | 0 | -36 | -24 | -22 | N/A |
| 9/30/2021 | 0 | -48 | -22 | -20 | N/A |
| 6/30/2021 | 0 | -35 | -17 | -15 | N/A |
| 3/31/2021 | 0 | -20 | -14 | -12 | N/A |
| 12/31/2020 | 0 | -18 | -11 | -9 | N/A |
| 12/31/2019 | 0 | -8 | -5 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CADL's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if CADL's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if CADL's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if CADL's revenue is forecast to grow faster than the US market.
High Growth Revenue: CADL is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CADL's Return on Equity is forecast to be high in 3 years time